Diabetic Neuropathic Pain - Pipeline Insight, 2026

DelveInsight's, "Diabetic Neuropathic Pain - Pipeline Insight, 2026" report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Diabetic Neuropathic Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Diabetic Neuropathic Pain: Understanding

Diabetic Neuropathic Pain: Overview

Diabetic neuropathic pain, most commonly associated with distal symmetric diabetic peripheral neuropathy (DPN), is a chronic complication of diabetes caused by progressive injury to peripheral sensory nerves. DPN is predominantly sensory, typically beginning in the feet and gradually progressing proximally in a characteristic "stocking-and-glove" pattern. It affects a substantial proportion of people with diabetes, with prevalence increasing with longer disease duration. Persistent neuropathic pain can substantially impair sleep, mobility, mood and overall quality of life.

Typical symptoms include burning, tingling, pins-and-needles sensations, stabbing or electric-shock-like pain, and increased sensitivity to normally non-painful stimuli. Pain often affects both feet symmetrically and may become more pronounced at night, while numbness and reduced temperature or vibration sensation can develop as the neuropathy progresses. Some patients remain asymptomatic despite objective nerve damage, increasing the risk of unnoticed foot trauma. Advanced sensory loss can contribute to foot ulcers, infections and lower-extremity amputation.

The underlying cause is multifactorial, with chronic hyperglycemia playing a central role in metabolic and microvascular injury to peripheral nerves. Hyperglycemia can promote oxidative stress, mitochondrial dysfunction, abnormal polyol and advanced-glycation pathways, and impaired nerve blood flow, ultimately causing axonal degeneration and nerve dysfunction. In type 2 diabetes, additional metabolic risk factors such as obesity, dyslipidemia and hypertension can contribute to neuropathy development and progression. Other causes of neuropathy, including alcohol, vitamin B12 deficiency, neurotoxic medications, kidney disease and thyroid disorders, should also be excluded.

Diagnosis is primarily clinical and involves assessment of symptoms, neurological examination and testing of small- and large-fiber function using pinprick, temperature, vibration, reflexes and a 10-g monofilament test. Nerve-conduction studies or electromyography are generally reserved for atypical presentations or diagnostic uncertainty. Management focuses on optimizing glycemic, weight, blood-pressure and lipid control, although established nerve damage cannot currently be reversed. For painful DPN, recommended pharmacological options include gabapentinoids, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants and sodium-channel blockers, with treatment individualized according to efficacy, tolerability and comorbidities; opioids are generally discouraged.

"Diabetic Neuropathic Pain- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic Neuropathic Pain pipeline landscape is provided which includes the disease overview and Diabetic Neuropathic Pain treatment guidelines. The assessment part of the report embraces, in depth Diabetic Neuropathic Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Neuropathic Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Neuropathic Pain R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic Neuropathic Pain.

Diabetic Neuropathic Pain Emerging Drugs Chapters

This segment of the Diabetic Neuropathic Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Diabetic Neuropathic Pain Emerging Drugs

LY4065967: Eli Lilly and Company

LY4065967 is an investigational oral small-molecule angiotensin II type 2 receptor (AT2R) antagonist being developed by Eli Lilly as a non-opioid approach for chronic pain. By blocking AT2R signaling, it is intended to modulate pain pathways involved in neuropathic pain. It is being evaluated in Phase II for diabetic peripheral neuropathic pain (DPNP) in the NP07 study, with approximately 150 participants. The study is randomized and placebo-controlled, assessing changes in average pain intensity as the primary efficacy outcome.

HRS-2129: Jiangsu Hengrui Pharmaceuticals

HRS-2129 is an investigational oral small-molecule analgesic being developed by Hengrui Medicine for diabetic peripheral neuropathic pain (DPNP) and other pain conditions. It is being evaluated in a Phase Ib randomized, double-blind, placebo- and pregabalin-controlled study in 168 Chinese patients with DPNP. The study is assessing two HRS-2129 dose levels against placebo and pregabalin, with change in average daily pain score at Week 4 as the primary efficacy endpoint.

Diabetic Neuropathic Pain: Therapeutic Assessment

This segment of the report provides insights about the different Diabetic Neuropathic Pain drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Diabetic Neuropathic Pain
• There are approx. 10+ key companies which are developing the therapies for Diabetic Neuropathic Pain. The companies which have their Diabetic Neuropathic Pain drug candidates in the mid stage, i.e. Phase II include, Eli Lilly and Company.
• Phases

DelveInsight's report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Diabetic Neuropathic Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Diabetic Neuropathic Pain: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Diabetic Neuropathic Pain therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic Neuropathic Pain drugs.

Diabetic Neuropathic Pain Report Insights

• Diabetic Neuropathic Pain Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Diabetic Neuropathic Pain Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Diabetic Neuropathic Pain drugs?
• How many Diabetic Neuropathic Pain drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic Neuropathic Pain?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Diabetic Neuropathic Pain therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Diabetic Neuropathic Pain and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Eli Lilly and Company
• Jiangsu Hengrui Pharmaceuticals
• Vertex Pharmaceuticals
• Zhejiang Hanmai Pharmaceutical Technology
• Trevena

Key Products

• LY4065967
• HRS-2129
• VX-993
• YJ001
• TRV045